Immunomodulatory Effects of IVIG in Humoral Immunodeficiency

What are the immunomodulatory mechanisms of intravenous immunoglobulin in primary humoral immunodeficiency?

Intravenous immunoglobulin exerts immunomodulatory effects in primary humoral immunodeficiency through biphasic cytokine modulation, partial T cell reconstitution, dual B cell activation and selective depletion via anergy induction, and normalization of antigen-presenting cell function, with these mechanisms operating through distinct temporal phases and varying by patient subtype and cellular context.

Abstract

Intravenous immunoglobulin therapy in primary humoral immunodeficiency exerts immunomodulatory effects through multiple interconnected mechanisms that extend beyond passive antibody replacement. IVIG produces biphasic cytokine modulation, with acute elevation of IL-2, IL-10, IL-6, IL-8, and TNF-α at 30-60 minutes post-infusion, followed by sustained down-regulation of the IL-1 system through increased IL-1 receptor antagonist and neutralizing antibodies. T cell compartments show partial restoration of CD4+ counts (p<0.05) and acute increases in regulatory T cells (p=0.006), while CD8+ T cell activation decreases over 6-12 months. B cell effects are complex: IVIG induces proliferation and immunoglobulin synthesis at replacement doses, yet simultaneously drives B cells toward an anergic state characterized by increased constitutive ERK activation, down-regulation of CD21 expression, and differentiation into apoptosis-prone CD21low B cells, resulting in selective B cell depletion. IVIG also modulates antigen-presenting cells, partially restoring myeloid dendritic cell numbers while reducing activation markers CD80, CD83, and CD40.

These mechanisms display apparent contradictions that resolve through temporal dynamics, with acute activation (minutes to hours) transitioning to sustained regulation (days to months), and through context-dependent effects varying by patient subtype, cell population, and activation pathway. Effects on IgG versus IgA/IgM production differ between IgG subclass deficiency and CVID patients, while certain T cell subsets like Tregs and iNKT cells fail to normalize despite improvements in other compartments. The immunomodulatory actions appear to operate through pathway-selective modulation rather than uniform immune activation or suppression, with IVIG simultaneously providing missing immune functions while constraining excessive inflammation and depleting potentially autoreactive B cell clones.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question. More on methods

Characteristics of Included Studies

All 10 included sources investigated immunomodulatory mechanisms of IVIG in patients with primary humoral immunodeficiencies. The majority focused on common variable immunodeficiency (CVID), with two studies examining broader primary hypogammaglobulinemia populations and one investigating both IgG subclass deficiency and CVID.

IVIG Treatment Protocols

IVIG administration protocols varied across studies, with doses ranging from 300-400 mg/kg and different sampling timepoints for mechanistic assessments.

Sample collection timing varied substantially, with acute effects measured at 30 minutes to 1 hour post-infusion, intermediate effects at 7 days, and longer-term effects at 2 weeks to 6-12 months. This heterogeneity in measurement timepoints is important for interpreting the temporal dynamics of different immunomodulatory mechanisms.

Immunomodulatory Mechanisms

Cytokine Modulation

IVIG therapy demonstrated complex effects on cytokine networks, with both pro-inflammatory and anti-inflammatory changes observed across different timepoints and patient populations.

Before IVIG treatment, CVID patients exhibited higher baseline levels of IL-2 (p=0.045), IL-10 (p=0.002), IL-6, IL-8, IL-1Ra, and TNF-α compared to healthy controls. IVIG infusion acutely elevated IL-2 and IL-10 levels further at 30 minutes post-infusion, suggesting initial immune activation. Similarly, IL-6, IL-8, IL-1Ra, and TNF-α increased significantly 1 hour after infusion. A significant correlation was observed between IL-1Ra and TNF-α changes, with an associative trend between IL-6 and IL-8.

In contrast to these pro-inflammatory changes, IVIG also demonstrated down-regulatory effects on the IL-1 system. Aukrust et al. observed a marked increase in IL-1 receptor antagonist (IL-1Ra) and neutralizing antibodies against IL-1α, coupled with moderate decreases in IL-1α and IL-1β levels. Soluble IL-1 receptor type II levels increased significantly, while soluble IL-1 receptor type I decreased. These changes impaired the ability of IL-1 to stimulate peripheral blood mononuclear cells for TNF-α release, demonstrating functional down-regulation of inflammatory pathways. Pooled serum obtained after IVIG infusion suppressed lipopolysaccharide- and staphylococcal enterotoxin B-stimulated IL-1α and IL-1β release, but not phorbol myristate acetate-stimulated release.

Immunomodulatory effects persisted beyond acute timepoints. Effects were detectable at 7 days post-infusion in in vitro assays and at 2 weeks in vivo, indicating sustained immune modulation. However, the specific duration of cytokine changes and time to return to baseline were not systematically characterized across studies.

T Cell Effects

IVIG therapy induced multiple changes in T cell populations and activation states, with effects varying by timepoint and T cell subset.

At baseline, newly diagnosed CVID patients displayed suppressed CD4 T cell counts and elevated immune activation in both CD8 and CD4 T cells. IVIG treatment produced rapid increases in CD4+ T cells (p=0.028) and regulatory T cells (p=0.006) at 30 minutes post-infusion. Over longer timeframes of 6-12 months, IVIG therapy partially restored CD4 T cell counts, with six out of nine patients showing increased levels.

CD8 T cell responses were more complex. Acutely, IVIG increased circulating CD8+ lymphocyte numbers, reflected in a significant decrease in the CD4+/CD8+ ratio. However, this was accompanied by down-regulation of CD8+ lymphocyte activity, as evidenced by decreased soluble CD8 antigen/CD8+ lymphocyte ratio. At 6-12 months, treatment reduced CD8 T cell activation markers, with decreased Ki67 expression, reduced CD38 intensity, and lower frequencies of CD38+HLA-DR+ CD8 cells.

Interestingly, regulatory T cell (Treg) and invariant natural killer T cell (iNKT) levels remained low despite IVIG treatment in the 6-12 month timeframe, with reduced expression of activation markers CD161 and PD-1 on iNKT cells. This suggests differential effects on distinct T cell subsets, with some populations failing to normalize despite improvements in other compartments.

Functional T cell assays demonstrated IVIG-induced down-modulation of mitogen-stimulated lymphocyte proliferation in vitro, which correlated significantly with increased plasma neopterin levels, suggesting monocyte/macrophage activation.

B Cell Effects

IVIG exerted profound effects on B cell function, differentiation, and survival, representing a central mechanism of immune modulation in primary humoral immunodeficiency.

IVIG at replacement doses induced B cell proliferation and immunoglobulin synthesis from CVID patient B cells, providing T-independent signaling that rectified defective signaling normally provided by T cells. This B cell stimulation was not associated with induction of effector cytokine IFN-γ or transcription factor T-bet, suggesting selective activation pathways.

The effects on immunoglobulin production varied by isotype and patient subtype. In patients with IgG subclass deficiency, IVIG suppressed polyclonally stimulated IgA and IgM production, while positively stimulating IgG production in both IgG subclass deficiency and CVID patients. IgG production after IVIG infusion was significantly higher than in healthy donors. Co-stimulation with concanavalin A revealed differential effects: in IgG subclass deficiency patients, ConA inhibited IgG production, whereas in CVID patients, ConA co-stimulation increased IgG production after IVIG infusion.

IVIG therapy interfered with B cell receptor (BCR) signaling by increasing constitutive ERK activation while reducing phosphorylated ERK increment induced by BCR cross-linking. This pattern is characteristic of anergic B cells. IVIG also induced down-regulation of CD21 expression on B cells, driving differentiation into CD21low B cells that are anergic-like and apoptosis-prone. These newly generated CD21low B cells underwent spontaneous apoptosis upon in vitro culture, contributing to B cell depletion. IVIG infusion was rapidly followed by a significant decrease in circulating B cell numbers, with no corresponding effects on T cell or natural killer cell counts.

Additional B cell mechanisms included modulation through FcγRIIB receptor and CD22, inhibition of TLR-9 and TLR7-mediated B cell activation, and neutralization of BAFF and proliferation-inducing ligand. FcγRIIb expression on CD19+ B cells was elevated at baseline in CVID patients (p=0.0119) but was not significantly affected by IVIG infusion.

Antigen-Presenting Cell Effects

IVIG modulated the function and activation state of antigen-presenting cells, particularly myeloid dendritic cells (mDCs) and monocytes/macrophages.

Before treatment, CVID patients had suppressed myeloid dendritic cell levels with elevated expression of co-stimulatory receptors CD80 and CD83, which correlated with T cell activation markers. IVIG therapy over 6-12 months partially restored mDC numbers and reduced activation markers, with significant decreases in CD40 and CD80 levels on mDCs.

Monocyte/macrophage activation showed biphasic effects. Acutely, IVIG increased plasma neopterin levels, indicating in vivo activation of monocytes/macrophages. However, functional assays revealed decreased zymosan-stimulated reactive oxygen species (ROS) generation from monocytes, while phorbol myristate acetate-stimulated ROS generation remained unchanged. This suggests differential effects on distinct monocyte activation pathways.

Soluble CD14 (sCD14), a marker of monocyte activation, was elevated in treatment-naïve CVID patients. The modulation of macrophages and dendritic cells represented one of several proposed mechanisms of IVIG action.

Fc Receptor-Mediated Mechanisms

Fc receptor engagement represented a key pathway for IVIG immunomodulation, though direct effects varied across studies.

FcγRIIb receptor interactions were investigated in multiple contexts. IVIG modulated B cells through FcγRIIb and CD22, with FcγRIIb playing a role in maintaining immune tolerance by regulating BCR signaling. Before IVIG treatment, CVID patients had significantly higher expression of FcγRIIb on CD19+ B cells compared to healthy controls (p=0.0119). However, IVIG infusion did not significantly affect FcγRIIb expression, suggesting effects may be mediated through receptor engagement rather than expression changes.

Fc receptor blockade was identified as one mechanism of IVIG action in autoimmune and inflammatory disorders, though its specific contribution in primary humoral immunodeficiency contexts remained less well-defined. The interaction between IVIG and Fc receptors likely contributes to multiple downstream effects including modulation of cytokine release, cell activation states, and antibody-dependent cellular functions.

Synthesis

The immunomodulatory mechanisms of IVIG in primary humoral immunodeficiency display apparent contradictions in direction of effect, particularly regarding pro-inflammatory versus anti-inflammatory changes and cellular activation versus suppression. These divergent findings can be reconciled through consideration of temporal dynamics, measurement contexts, and mechanistic complexity.